TWiV 1048: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses a molnupiravir-associated mutational signature in global SARS-CoV-2 genomes, inhaled fluticasone furoate for outpatient treatment of COVID-19, optimal duration of systemic corticosteroids in COVID-19 treatment, early antibody treatment, inflammation, and risk of post-COVID conditions, autonomic dysregulation in long-term patients suffering from post-COVID-19 syndrome assessed by heart rate variability, and multiorgan MRI findings after hospitalization with COVID-19 in the UK.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Molnupiravir-associated mutational signature in global SARS-CoV-2 genomes (Nature)
• Inhaled fluticasone furoate for outpatient treatment of COVID-19 (NEJM)
• Optimal duration of systemic corticosteroids in COVID-19 treatment (OFID)
• Distinguishing features of Long COVID identified through immune profiling (Nature)
• Early antibody treatment, inflammation, and risk of post-COVID conditions (mBIO)
• Autonomic dysregulation in long-term patients suffering from post COVID-19 syndrome (SR)
• Multiorgan MRI findings after hospitalization with COVID-19 in the UK (The Lancet)
• Contribute to our Floating Doctors fundraiser at PWB
• Letters read on TWiV 1048
• Dr. Griffin's COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]